Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Single Center, Open Label, Phase 1 Study to Evaluate the Safety, Tolerability and Exploratory Efficacy of SNK01 in Subjects With Alzheimer's Disease (AD)

NCT04678453 is registered in ClinicalTrials.gov with NKGen Biotech, Inc. as lead sponsor.

NCT NCT04678453
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04678453 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Single Center, Open Label, Phase 1 Study to Evaluate the Safety, Tolerability and Exploratory Efficacy of SNK01 in Subjects With Alzheimer's Disease (AD)
Lead sponsor
NKGen Biotech, Inc.
Phase
Phase 1
Overall status
Terminated
Start date
January 6, 2021
Completion date
January 31, 2024
Enrollment
10 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer disease, neuro-degenerative disease